ICON Strategic Solutions provide insights on customised FSP models to enable the most flexible and efficient operating models for Sponsors.
In this whitepaper, ICON’s experts address our commitment to four main objectives to reducing the CRA drought.Download the whitepaper
For mid-size pharma, CRO and FSP models may evolve as the company grows. This either/or decision often means switching models by switching suppliers. By harnessing the ‘Embedded Blended’ model, all sponsors can benefit from a synchronised outsourcing strategy.Download the whitepaper
Presenting a unique approach to evolve the traditional local clinical development model in Japan, while lowering costs, improving productivity, and potentially accelerating drug approval timelines.Download the whitepaper
ICON is currently engaging with the Tufts CSDD - with input and in collaboration with ICON’s biopharmaceutical company Partners of Choice (PoC) - and invites input into a proposed new taxonomy and framework to redefine CRO sourcing model terminology.
John Barry, SVP and Chief Strategy Officer of ICON’s Strategic Solutions Division, considers the benefits of a blended model that combines FSP scale and CRO project-based sourcing for mid-size pharmaceutical and biotech companies.
John Barry and Brian Swindley offer their insights on the options available to pharma companies when delivering their clinical trial portfolios.
This spotlight feature authored by ICON's Barry Balfe examines how pharmaceutical companies are increasing their functional service partnership expenditure at a rapid rate, and the key considerations in selecting and executing the FSP model which are being overlooked. (PDF)
Learn more about the best practices for KPI creation and management in this blog.
As clinical development services and outsourcing models have become more complex, we have outgrown old definitions these models. This blog explores the new framework for defining CRO sourcing models and explains its importance.
As the market for outsourcing continues to grow, so too have the types of outsourcing models available to sponsors.
Japan is the third-largest consumer of ethical drugs and the world’s third-largest economy; therefore, it is an important development centre for new medicines. However, there are various cultural and economic challenges in Japan that make it difficult to manage a fixed workforce against a variable portfolio of clinical research.
ICON is the world's leading provider of Functional Service Provision (FSP). Through our global Strategic Solutions, we provide strategic outsourcing consulting, advising on organisational models, transformational roadmaps and operational execution, with full management oversight. We have deployed FSP solutions across all major functions from clinical monitoring and project management through data management, statistical programming and beyond.Read more